Profile data is unavailable for this security.
About the company
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
- Revenue in ILS (TTM)42.18m
- Net income in ILS-177.85m
- Incorporated2003
- Employees79.00
- LocationBioline Rx LtdModi'in Technology Park2 HaMa'ayan StreetMODIIN 7177871IsraelISR
- Phone+972 86429100
- Fax+972 86429101
- Websitehttps://www.biolinerx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purple Biotech Ltd | 0.00 | -67.90m | 47.78m | 20.00 | -- | 0.3811 | -- | -- | -0.2679 | -0.2679 | 0.00 | 0.4086 | 0.00 | -- | -- | 0.00 | -40.57 | -37.24 | -47.99 | -41.28 | -- | -- | -- | -9,415.70 | -- | -- | 0.0098 | -- | -- | -- | 8.25 | -- | -28.45 | -- |
| X T L Biopharmaceuticals Ltd | 1.64m | -81.38m | 48.73m | 33.00 | -- | 0.599 | -- | 29.66 | -0.3695 | -0.3695 | 0.0075 | 0.1493 | 0.0192 | -- | 0.7012 | 49,784.54 | -94.96 | -53.17 | -111.98 | -59.10 | -- | -2.33 | -4,953.75 | -1,084.42 | -- | -- | 0.00 | -- | -85.80 | -- | -7.97 | -- | -53.12 | -- |
| Matricelf Ltd | 0.00 | -13.83m | 57.22m | -- | -- | 2.12 | -- | -- | -0.8777 | -0.8777 | 0.00 | 1.67 | 0.00 | -- | -- | -- | -39.69 | -- | -42.80 | -- | -- | -- | -- | -- | -- | -- | 0.0527 | -- | -- | -- | -10.77 | -- | -- | -- |
| DNA Group TR Ltd | 306.00k | -1.18m | 87.20m | 14.00 | -- | 1.10 | -- | 284.97 | -0.0088 | -0.0088 | 0.0025 | 0.6429 | 0.0038 | -- | 1.37 | 21,857.14 | -1.45 | -23.54 | -1.46 | -26.27 | -- | -- | -384.64 | -7,406.24 | -- | -- | 0.00 | -- | -45.36 | -- | 95.00 | -- | -- | -- |
| Bonus Biogroup Ltd | 0.00 | -28.84m | 178.69m | 58.00 | -- | 8.13 | -- | -- | -0.0675 | -0.0675 | 0.00 | 0.0188 | 0.00 | -- | -- | 0.00 | -54.73 | -76.10 | -63.36 | -97.19 | -- | -- | -- | -- | -- | -- | 0.331 | -- | -- | -- | 26.29 | -- | 19.30 | -- |
| BioLine RX Ltd | 42.18m | -177.85m | 208.43m | 79.00 | -- | 4.00 | -- | 4.94 | -0.184 | -0.184 | 0.042 | 0.0435 | 0.1939 | -- | 6.40 | 533,872.80 | -81.75 | -52.74 | -127.94 | -65.43 | 55.84 | -- | -421.69 | -3,501.79 | 1.05 | -519.43 | 0.4642 | -- | -- | -- | -142.93 | -- | -50.72 | -- |
| Compugen Ltd | 130.34m | -60.37m | 618.81m | 68.00 | -- | 2.72 | -- | 4.75 | -0.685 | -0.685 | 1.48 | 2.41 | 0.3638 | -- | 11.29 | 1,916,740.00 | -16.85 | -28.41 | -20.51 | -32.57 | 88.60 | 92.40 | -46.32 | -293.48 | -- | -- | 0.00 | -- | 346.12 | 13.45 | 44.34 | -- | 1.71 | -- |
Data as of Jul 16 2024. Currency figures normalised to Bioline Rx Ltd's reporting currency: Israeli Shekel ILS
0.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| KSM Mutual Funds Ltd.as of 30 Apr 2024 | 5.40m | 0.45% |
| Meitav Mutual Funds Ltd.as of 30 Apr 2024 | 2.69m | 0.22% |
| Migdal Mutual Funds Ltd.as of 30 Apr 2024 | 1.36m | 0.11% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 761.09k | 0.06% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 311.89k | 0.03% |
| Psagot Mutual Funds Ltd.as of 30 Apr 2024 | 254.12k | 0.02% |
| Harel Mutual Funds Ltd.as of 30 Apr 2024 | 118.77k | 0.01% |
More ▼
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
